Antisoma Advances AS1411 Aptamer In Kidney Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Renal tumors and acute myeloma will serve as launch pad for trials in a range of solid and blood cancers.
You may also be interested in...
Novartis’ RAD001 Doubles Progression-Free Survival in Advanced Renal Cancer Trial
Median PFS was 4 months with everolimus, versus 1.9 months with placebo.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.